GSK 
Welcome,         Profile    Billing    Logout  
 323 Products   957 Diseases   323 Products   1261 Trials   64041 News 


12345678910111213...747748»
  • ||||||||||  Jemperli (dostarlimab-gxly) / GSK, Zejula (niraparib) / GSK, J&J
    Trial completion date, Trial primary completion date, Combination therapy:  Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (clinicaltrials.gov) -  May 8, 2024   
    P2,  N=66, Recruiting, 
    Considering their dismal prognosis, further investigation is warranted to test the use of PARPi in uLMS, and particularly in the setting of BRCA1/2 alterations. Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    Journal:  The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis. (Pubmed Central) -  May 8, 2024   
    Patients receiving natalizumab, ocrelizumab, ofatumumab, or rituximab at a tertiary multiple sclerosis center were invited to take an online survey interrogating their monoclonal antibody experience...The wearing-off phenomenon is common, associated with depression, and reduces treatment satisfaction. Research addressing mitigation strategies is needed.
  • ||||||||||  GW-2580 / GSK, TL-1-85 / Massachusetts General Hospital, Wellcome Sanger Institute
    Journal:  Prognostic value and immunological role of MMRN1: a rising star in cancer. (Pubmed Central) -  May 8, 2024   
    Our analysis demonstrated a significant relationship between MMRN1 and prognosis, tumor immunity, and drug sensitivity of several tumors. As a rising star in cancer, it needs further research.
  • ||||||||||  Benlysta (belimumab) / GSK, Lupkynis (voclosporin) / Aurinia Pharma, Saphnelo (anifrolumab) / AstraZeneca
    Review, Journal:  Systemic Lupus Erythematosus: A Review. (Pubmed Central) -  May 7, 2024   
    Hydroxychloroquine is first-line therapy and reduces disease activity, morbidity, and mortality. When needed, additional immunosuppressive and biologic therapies include azathioprine, mycophenolate mofetil, cyclophosphamide, belimumab, voclosporin, and anifrolumab.
  • ||||||||||  Nucala (mepolizumab) / GSK
    Journal:  A tailored approach to refractory severe Mepolizumab-associated headache: a case study. (Pubmed Central) -  May 7, 2024   
    Our experience indicates that a tailored strategy for managing severe asthmatic patients, who have experienced side effects from biologic drugs, can be effective in maintaining drug efficacy while minimizing side effects. Further studies on a larger number of patients are required to demonstrate whether the positive outcomes here described are replicable on a larger scale.
  • ||||||||||  Nucala (mepolizumab) / GSK
    Journal:  The Role of ACT Score in Mepolizumab Discontinuation. (Pubmed Central) -  May 7, 2024   
    In this real-world study, we find that high eosinophil count may not be adequate in screening which individuals will benefit from mepolizumab. Up to 17% of patients fail therapy within 6 months, with male sex and low ACT score increasing risk of mepolizumab discontinuation at Cleveland Clinic.
  • ||||||||||  EZM2302 / GSK, Ipsen
    Preclinical, Journal:  A CARM1 Inhibitor Potently Suppresses Breast Cancer Both In Vitro and In Vivo. (Pubmed Central) -  May 7, 2024   
    The combination of iCARM1 with either endocrine therapy drugs or etoposide demonstrated synergistic effects in inhibiting the growth of breast tumors. In summary, targeting CARM1 by iCARM1 effectively suppresses breast tumor growth, offering a promising therapeutic approach for managing breast cancers in clinical settings.
  • ||||||||||  Arexvy (respiratory syncytial virus vaccine, adjuvanted) / GSK, Abrysvo (PF-06928316) / Pfizer
    Review, Journal:  Respiratory Syncytial Virus Infection in Older Adults: An Update. (Pubmed Central) -  May 7, 2024   
    There is an urgent need for antivirals and preventive strategies in this population, particularly in individuals at higher risk of severe outcomes following RSV infection. In this review, we describe prevention and treatment strategies for RSV illnesses, with a deep focus on the novel data on vaccination that has become available (Arexvy, GSK, and Abrysvo, Pfizer) for older adults.
  • ||||||||||  GSK3965193 / GSK
    Journal:  TRPV4 modulation participates in paraoxon-induced brain injury via NMDA and NLRP3 regulation. (Pubmed Central) -  May 7, 2024   
    In vivo, we examined the survival rate, behavioral seizures, histopathological alterations, NMDA receptor phosphorylation, as well as the expression of the NLRP3-ASC-caspase-1 complex and downstream inflammatory factors in the POX poisoning model following intervention with the TRPV4 antagonist GSK2193874...Moreover, the TRPV4 antagonist corrected the NMDA-induced increase in inward current and cell death rate, decrease in cell viability, and Ca2+ accumulation. TRPV4 participates in the mechanisms of brain injury induced by POX exposure through NMDA-mediated excitotoxicity and NLRP3-mediated inflammatory response.
  • ||||||||||  Nulojix (belatacept) / BMS
    Tailored De Novo Belatacept Regimens: Long-Term Clinical Outcomes in Adolescent Kidney Transplantation (107-AB, Level 1) -  May 6, 2024 - Abstract #ATC2024ATC_2903;    
    All 7 patients received intra-operative alemtuzumab and methylprednisolone induction and belatacept maintenance therapy...Of these, two converted from sirolimus to steroids and mycophenolate mofetil (MMF)...One patient was maintained on belatacept and belimumab to prevent lupus recurrence... Tailored belatacept-based regimens demonstrate favorable long-term outcomes in a patient population who are susceptible to allograft dysfunction and medication nonadherence.
  • ||||||||||  Tavegil (clemastine) / GSK
    Clemastine Fumarate Suppresses Mouse Heart Transplantation Acute Rejection by Targeting T Cells (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_2287;    
    Further studies are needed to assess optimal duration. CF can significantly alleviate acute rejection of heart transplantation in mice, by inhibiting T cells proliferation, reducing the proportions of Th1 cells and decreasing proinflammatory cytokines level.
  • ||||||||||  Arexvy (respiratory syncytial virus vaccine, adjuvanted) / GSK, Abrysvo (PF-06928316) / Pfizer
    Heterogenous Respiratory Syncytial Virus Vaccine Immunogenicity in Solid Organ Transplant Recipients (Ballroom AB, Level 3) -  May 6, 2024 - Abstract #ATC2024ATC_2033;    
    CF can significantly alleviate acute rejection of heart transplantation in mice, by inhibiting T cells proliferation, reducing the proportions of Th1 cells and decreasing proinflammatory cytokines level. Therefore, we sought to evaluate the humoral vaccine response to clinically available RSV vaccines in this at-risk population.* In a national prospective cohort, we measured Anti-RSV Pre-Fusion F IgG antibody (PreF Ab) using the Meso Scale Diagnostics respiratory panel 1 in SOTRs who received the RSVPreF3 (GSK, AREXVY
  • ||||||||||  Livtencity (maribavir) / Takeda, GSK
    Results from the French Compassionate Program of Maribavir Use for Refractory CMV Infection/Disease (117, Level 1) -  May 6, 2024 - Abstract #ATC2024ATC_1861;    
    P3
    The population analyzed differed from the SOLSTICE population in that it had a higher proportion of SOT recipients, with CMV disease, more severe biological criteria and with identified antiviral resistance. Despite the more severe CUP patient profiles, the results showed coherent efficacy and safety findings with the pivotal study.
  • ||||||||||  Prolia (denosumab) / Amgen
    Denosumab-Induced Severe Hypocalcemia with Recurrent Side Effects (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1652;    
    Denosumab-induced hypocalcemia is rare, but due to its severe effects on neuromuscular and cardiac function, patients should be counseled on the symptoms of hypocalcemia to ensure prompt medical evaluation. Ultimately, treatment for post-LTx osteoporosis should be individualized with consideration of specific medical history as well as routine monitoring of calcium levels when prescribed denosumab.
  • ||||||||||  Prolia (denosumab) / Amgen
    Effect of Denosumab on Mineral and Bone Disorder in Kidney Transplant Recipients: A Preliminary Study (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1644;    
    Our results suggested that Denosumab can reduce the level of bone turnover markers in kidney transplant recipients and has a good safety profile. The long-term effects on bone metabolism and bone mineral density after kidney tranplantation need to be further investigated.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Livtencity (maribavir) / Takeda, GSK
    Real World Experience of Maribavir Use for Cytomegalovirus Infection after Kidney Transplantation (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1412;    
    Most common adverse reactions included taste alteration, GI upset, and fatigue. There was no indication for empiric tacrolimus dose adjustments upon initiating maribavir, but levels should be closely monitored for possible dose reduction in some patients.
  • ||||||||||  Comparative Effectiveness of Outpatient COVID-19 Therapies in Solid Organ Transplant Recipients (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_904;    
    SOTRs who received outpatient mAb or antiviral treatment for mild-to-moderate COVID-19 had comparable clinical outcomes, as measured by odds of hospitalization. Clinicians may use any of these treatment options according to the individual patient's circumstances and without concern for differential therapeutic efficacy.
  • ||||||||||  Leukeran (chlorambucil) / GSK
    Review, Journal:  Pharmacology of drugs used in autoimmune dermatopathies in cats and dogs: A narrative review. (Pubmed Central) -  May 6, 2024   
    This review paper will focus on the mechanism of action, pharmacokinetics and pharmacodynamics, clinical uses and adverse effects of immunosuppressive drugs used to treat autoimmune dermatoses in cats and dogs. These include glucocorticoids, ciclosporin A, azathioprine, chlorambucil, mycophenolate mofetil, oclacitinib and Bruton's tyrosine kinase inhibitors.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective. (Pubmed Central) -  May 6, 2024   
    Of particular note, clinical and preclinical studies suggest that commonly prescribed osteoporosis drugs like bisphosphonates, intermittent parathyroid hormone, anti-sclerostin antibody, selective estrogen receptor modulators and anti-receptor activator of nuclear factor-kappa B ligand inhibitor denosumab may also relieve back pain. Here, we cite clinical and preclinical studies and include unpublished data to support the argument that a subset of these therapeutics for osteoporosis may alleviate low back pain by also targeting the IVD.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  Use of botox for sialorrhea and dysphagia in the neonatal population. (Pubmed Central) -  May 5, 2024   
    BoNT injection is a safe, non-invasive alterative for management of sialorrhea in neonates. Further extensive study needs to be performed to identify the optimal dose per gland in this population.